月経前症候群治療市場規模、シェア、成長分析、製品別、薬剤の種類別、流通チャネル別、地域別 - 産業予測、2025年～2032年

月経前症候群治療の世界市場規模は2023年に13億9,000万米ドルと評価され、2024年の14億4,000万米ドルから2032年には18億9,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは3.42％で成長する見通しです。

世界の月経前症候群（PMS）治療市場は、PMSとその女性の健康への影響に対する意識の高まりと、効果的な治療オプションに対する需要によって成長を遂げています。個別化や非侵襲的な方法を重視するヘルスケア動向と歩調を合わせ、非ホルモン治療や統合治療へのシフトが顕著です。市場の主な企業は、革新的な治療法を導入するために研究開発に投資している著名な製薬会社やヘルスケア企業です。しかし、治療へのアクセスを長引かせる規制上のハードルや、標準化された治療プロトコルの欠如などの課題も残っており、その結果、患者の転帰にばらつきが生じています。PMS追跡アプリを含むデジタルヘルスソリューションの統合は、データプライバシーとセキュリティに関する懸念を引き起こし、業界が進化し続ける中で強固なデータ保護の必要性を強調しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 顧客購買行動分析

月経前症候群治療市場規模：製品別& CAGR（2025-2032）

• 市場概要
• 処方箋
• 市販薬（OTC）

月経前症候群治療市場規模：薬剤の種類別& CAGR（2025-2032）

• 市場概要
• 鎮痛剤
• 抗うつ薬
• 経口避妊薬と卵巣抑制剤

月経前症候群治療市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• ドラッグストアと薬局
• 病院薬局
• オンライン薬局

月経前症候群治療市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• Bayer AG
• Eli Lilly and Company
• GlaxoSmithKline Plc
• Pfizer Inc.
• AbbVie Inc.
• H. Lundbeck A/S
• Dr. Reddy's Laboratories Ltd
• BASF SE
• SHIONOGI & Co. Ltd
• Asarina Pharma AB
• Teva Pharmaceutical Industries Ltd
• Vistagen Therapeutics
• Herbalife International of America, Inc.
• The Nature's Bounty Co.
• Johnson & Johnson Services

結論と提言

Global Premenstrual Syndrome Treatment Market size was valued at USD 1.39 Billion in 2023 and is poised to grow from USD 1.44 Billion in 2024 to USD 1.89 Billion by 2032, growing at a CAGR of 3.42% in the forecast period (2025-2032).

The global premenstrual syndrome (PMS) treatment market is experiencing growth driven by heightened awareness of PMS and its impact on women's health, coupled with a demand for effective treatment options. There is a noticeable shift toward non-hormonal and integrative treatments, aligning with broader healthcare trends emphasizing personalization and non-invasive methods. Key players in the market comprise prominent pharmaceutical and healthcare companies investing in research and development to introduce innovative therapies. However, challenges persist, such as regulatory hurdles that prolong treatment accessibility and a lack of standardized treatment protocols, resulting in varied patient outcomes. The integration of digital health solutions, including PMS tracking apps, raises concerns about data privacy and security, underscoring the necessity for robust data protection as the industry continues to evolve.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Premenstrual Syndrome Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Premenstrual Syndrome Treatment Market Segments Analysis

The global premenstrual syndrome treatment market is segmented into product, drug, distribution channel, and region. by product, the market is classified into Prescription and Over-the-Counter (OTC). Depending on the drug, it is divided into Analgesics, Antidepressants, and Oral Contraceptives & Ovarian Suppression Agents. According to distribution channel, the market is categorized into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Regionally, it is analyzed across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Driver of the Global Premenstrual Syndrome Treatment Market

The growing awareness of premenstrual syndrome (PMS) through public education initiatives and awareness campaigns has significantly boosted diagnosis rates, leading to a heightened demand for treatments. Efforts by organizations focused on PMS have played a crucial role in informing women about the condition and its symptoms, encouraging them to seek medical assistance. This increased understanding not only helps women manage their symptoms more effectively but also drives the market for various treatments, including oral contraceptives, as more individuals become proactive in addressing their health needs related to PMS. This trend is crucial in expanding the overall premenstrual syndrome treatment market.

Restraints in the Global Premenstrual Syndrome Treatment Market

The Global Premenstrual Syndrome Treatment market faces significant restraints due to the stigma surrounding mental health issues associated with PMS and the prevalent underreporting of symptoms. In various cultures, there exists a taboo that discourages open discussions among women regarding their experiences and symptoms, which subsequently leads to a decreased demand for treatment options such as antidepressants and hormonal therapies. This lack of awareness and unwillingness to seek help hampers the overall growth potential of the market, as many individuals may not pursue the necessary interventions to alleviate their discomfort and improve their quality of life.

Market Trends of the Global Premenstrual Syndrome Treatment Market

The Global Premenstrual Syndrome (PMS) Treatment market is witnessing a significant shift towards natural and holistic solutions, as consumers increasingly prioritize plant-based remedies over conventional pharmaceuticals. This trend reflects a growing awareness of wellness and the desire for sustainable treatment options. Herbal supplements rich in vitamin B6, calcium, and magnesium are becoming popular choices for alleviating PMS symptoms like cramping and mood swings. As wellness trends continue to flourish, businesses that offer herbal and plant-based treatments are capitalizing on this demand, positioning themselves favorably within a market that seeks effective, drug-free solutions to improve women's health.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Premenstrual Syndrome Treatment Market Size by Product & CAGR (2025-2032)

• Market Overview
• Prescription
• Over-the-Counter (OTC)

Global Premenstrual Syndrome Treatment Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Analgesics
• Antidepressants
• Oral Contraceptives & Ovarian Suppression Agents

Global Premenstrual Syndrome Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Drug Stores & Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Global Premenstrual Syndrome Treatment Market Size & CAGR (2025-2032)

• North America (Product, Drug Type, Distribution Channel)
  • US
  • Canada
• Europe (Product, Drug Type, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Drug Type, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Drug Type, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Drug Type, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline Plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BASF SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SHIONOGI & Co. Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Asarina Pharma AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vistagen Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Herbalife International of America, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• The Nature's Bounty Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations